Skip to main content

Acura Pharmaceuticals, Inc. (ACUR)

OTCMKTS: ACUR · Delayed Price · USD
0.5000 -0.0500 (-9.09%)
Sep 24, 2021 2:37 PM EDT - Market closed
Market Cap33.79M
Revenue (ttm)2.39M
Net Income (ttm)-1.57M
Shares Out42.89M
EPS (ttm)-0.05
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,500
Open0.5401
Previous Close0.5500
Day's Range0.5000 - 0.5401
52-Week Range0.1500 - 0.7500
Beta0.66
Analystsn/a
Price Target6.00 (+1,100.0%)
Est. Earnings Daten/a

About ACUR

Acura Pharmaceuticals, Inc., an innovative drug delivery company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six add...

IndustryPharmaceuticals
Founded1935
CEORobert Jones
Employees12
Stock ExchangeOTCMKTS
Ticker SymbolACUR
Full Company Profile

Financial Performance

In 2020, ACUR's revenue was $3.57 million, an increase of 34.36% compared to the previous year's $2.66 million. Losses were -$1.21 million, -67.99% less than in 2019.

Financial Statements

News

Acura Pharmaceuticals Announces Second Quarter 2021 Financial Results

PALATINE, Ill., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acura Pharmaceuticals, Inc. (OTCQB: ACUR), an innovative drug delivery company engaged in the research, development and commercialization of technologie...

1 month ago - GlobeNewsWire

Acura Pharmaceuticals and AD Pharma Amend License to LIMITx™ LTX-03

Amendment Extends NDA Acceptance Date Amendment Extends NDA Acceptance Date

2 months ago - GlobeNewsWire